VALIDATION OF PRO_10, A MULTIGENE PROGNOSTIC SIGNATURE, IN PATIENTS (PTS) WITH EARLY, ESTROGEN RECEPTOR POSITIVE (ER plus ) POSTMENOPAUSAL BREAST CANCER (BC)

被引：0
|
作者：
Moor, A. E. [1 ]
Guevara, C. [2 ]
Altermatt, H. J.
Jaggi, R. [1 ]
Aebi, S.
机构：
[1] Univ Bern, Dept Clin Res, Bern, Switzerland
[2] Univ Bern, Dept Pathol, CH-3000 Bern, Switzerland
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：80 / 80
页数：1
相关论文
共 50 条
  • [21] A phase I study of continuous (Con) and intermittent (Int) AZD2014 plus fulvestrant (F) in patients (pts) with estrogen receptor (ER plus ) metastatic breast cancer (BC).
    Hamilton, Erika Paige
    Patel, Manish R.
    Gluck, W. Larry
    Weise, Amy M.
    Pant, Shubham
    Jones, Suzanne Fields
    LoRusso, Patricia
    Kittaneh, Muaiad
    Cosulich, Sabina
    Harrington, Elizabeth A.
    Littlewood, Gillian
    Oelmann, Elisabeth Maria
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
    Bartlett, John M. S.
    Xu, Keying
    Wong, Jenna
    Pond, Gregory
    Zhang, Yi
    Spears, Melanie
    Salunga, Ranelle
    Mallon, Elizabeth
    Taylor, Karen J.
    Hasenburg, Annette
    Markopoulos, Christos
    Dirix, Luc
    van de Velde, Cornelis J. H.
    Rea, Daniel
    Schnabel, Catherine A.
    Treuner, Kai
    Bayani, Jane
    CLINICAL CANCER RESEARCH, 2024, 30 (08) : 1509 - 1517
  • [23] Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients
    Elisabetta Venturelli
    Annalisa Orenti
    Aline S. C. Fabricio
    Giulia Garrone
    Roberto Agresti
    Biagio Paolini
    Chiara Bonini
    Massimo Gion
    Franco Berrino
    Christine Desmedt
    Danila Coradini
    Elia Biganzoli
    BMC Cancer, 18
  • [24] Efficacy of fulvestrant in treating postmenopausal patients with estrogen receptor-positive metastatic breast cancer and prognostic analysis
    Li, Tao
    Jiao, Lianghe
    JOURNAL OF BUON, 2021, 26 (01): : 189 - 195
  • [25] Estrogen Receptor Positive/Progesterone Receptor Negative/(ER plus /PR-) Breast Cancer (BC) Has a Poor Response to Endocrine Therapy (ET)
    Guo, Tao
    Shen, Tiansheng
    Britt, Jacob
    Hameed, Omar
    Siegal, Gene P.
    Wei, Shi
    LABORATORY INVESTIGATION, 2017, 97 : 44A - 44A
  • [26] Estrogen Receptor Positive/Progesterone Receptor Negative/(ER plus /PR-) Breast Cancer (BC) Has a Poor Response to Endocrine Therapy (ET)
    Guo, Tao
    Shen, Tiansheng
    Britt, Jacob
    Hameed, Omar
    Siegal, Gene P.
    Wei, Shi
    MODERN PATHOLOGY, 2017, 30 : 44A - 44A
  • [27] Randomized comparison of adjuvant toremifene (Tor) versus tamoxifen (Tam) for postmenopausal women with node-positive (N plus ), estrogen receptor-positive (ER plus ) early stage breast cancer
    不详
    BREAST, 2005, 14 : S38 - S38
  • [28] Assessment of intratumoral heterogeneity in early stage estrogen receptor (ER) positive breast cancer
    Mastoraki, Sofia
    Navarro-Yepes, Juliana
    Tran, Tuan
    Sahin, Aysegul
    Hunt, Kelly
    Navin, Nicholas
    Keyomarsi, Khandan
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Elucidating the Mechanism of Action of Lenvatinib in Estrogen Receptor-Positive (ER plus ) Breast Cancer
    Gandasasmita, Natasha
    Vaidya, Gauri
    Datta, Arpita
    Marvalim, Charlie
    Lim, Joline Si Jing
    Lee, Soo Chin
    CANCER RESEARCH, 2024, 84 (08)
  • [30] The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts).
    Iyikesici, MS
    Kefeli, U
    Basaran, G
    Dane, F
    Ekenel, M
    Yumuk, PF
    Turhal, NS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 98S - 98S
12345